FREE Equity Delivery and MF
Flat ₹20/trade Intra-day/F&O
|
Dilip Davda recommend to "Avoid" the IPO.
Review By | Apply | May Apply | Neutral | Avoid | Not Rated |
---|---|---|---|---|---|
Count | 0 | 0 | 0 | 1 | 0 |
% | 0.00 | 0.00 | 0.00 | 100.00 | 0.00 |
Reviewer | Recommendation | Past Reviews |
---|---|---|
Dilip Davda | Avoid |
[Dilip Davda] This pharma/healthcare segment company has marked wild fluctuations in its bottom lines for the reported periods. Based on FY23 annualized earnings, the issue appears exorbitantly priced. It is operating in a highly competitive and fragmented segment. SPL’s debt level is also higher and raises concerns. There is no harm in skipping this pricey bet. Read detail review...
Sotac Pharmaceuticals IPO Reviews, analysis and views by popular members. Read Sotac Pharmaceuticals Limited IPO reviews by retail investors to find recommended ipo to buy.
Post Recommendation Manage Your IPO Reviews
Review By | Apply | May Apply | Neutral | Avoid |
---|---|---|---|---|
Count | 2 | 0 | 0 | 1 |
% | 66.67 | 0.00 | 0.00 | 33.33 |
Member | Review |
---|---|
CAhsBlr |
Avoid Avoid. |
mayank vadaliya |
Apply for Listing Gain at Upper Price Band good to invest looking from balance sheet. |
SANKETKP |
Apply for Long Term at Upper Price Band Having good clients and Long term growth benefits to customer and company. March 24, 2023 10:45:55 AM |
Post Recommendation Manage Recommendations
Note:
FREE Intraday Trading (Eq, F&O)
Flat ₹20 Per Trade in F&O
|